東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ null ]

切換: 標籤 | MARC模式 | ISBD

Paclitaxel-2'-O-pentadecylhemiglutar...

Hackett, Michael Joseph,

FindBook

Google Book

Amazon

博客來

Paclitaxel-2'-O-pentadecylhemiglutarate: A Prodrug Strategy for Albumin Based Drug Delivery /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Paclitaxel-2'-O-pentadecylhemiglutarate: A Prodrug Strategy for Albumin Based Drug Delivery // Michael Joseph Hackett.
作者:	Hackett, Michael Joseph,
面頁冊數:	1 electronic resource (179 pages)
附註:	Source: Dissertations Abstracts International, Volume: 73-05, Section: B.
Contained By:	Dissertations Abstracts International73-05B.
標題:	Pharmaceutical sciences. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3464917
ISBN:	9781124818016

Paclitaxel-2'-O-pentadecylhemiglutarate: A Prodrug Strategy for Albumin Based Drug Delivery /
Hackett, Michael Joseph,

Paclitaxel-2'-O-pentadecylhemiglutarate: A Prodrug Strategy for Albumin Based Drug Delivery /Michael Joseph Hackett. - 1 electronic resource (179 pages)

Source: Dissertations Abstracts International, Volume: 73-05, Section: B.

Delivery of antineoplastic agents to solid tumors remains a great challenge in formulation development. Preclinical successes often do not translate into clinical therapies due to the intrinsic imperfections of current models. The presented formulation begins with clinical observations indicating the ubiquitous protein, serum albumin, naturally accumulates selectively in spontaneously developed tumors. Albumin then provides a natural shuttle for therapeutic agents to solid tumors. To test this, a fatty diacid, 3-pentadecylglutaric acid (PDG), was synthesized. This fatty acid has the capacity to bind albumin tightly while concomitantly binding a therapeutic moiety, in this case paclitaxel. The paclitaxel-2'-O-pentadecylhemiglutarate conjugate binds albumin tightly but the extreme hydrophobicity led to poor loading efficiency and the formation of 120 nm albumin aggregates; a similar phenomenon observed in the clinically approved ABRAXANE. This aggregation was found to be the result of a specific interaction between paclitaxel and albumin. Dissociation of the conjugate from albumin is exceedingly slow with less than 3% released over 48 h under sink conditions. When administered to tumor bearing mice, the formulation behaved similarly to covalently attached albumin conjugates. Rapid and uniform organ distribution was observed followed by a slow re-emergence of complex into the vasculature giving rise to a half-life of 23 h. This is comparable to the half-life of the protein itself in mice. Tumor accumulation was moderate (∼1%) and biochemical stability analysis of the conjugate suggests little conversion (<6% over 72 h) to free drug would occur. Despite decreased cytotoxicity, lower doses of the conjugate demonstrated comparable efficacy to TAXOL without the need for surfactants. Modification of paclitaxel was accomplished in a single step using PDG anhydride presenting a cost-effective method for improving the pharmacokinetics of a drug. Conceptually, this study lays the foundation for using the PDG technology for modifying other therapeutic agents. The success of the formulation is highly dependent on the selected therapeutic modality which can be broadly limited to any therapeutic agent bearing a nucleophilic moiety. It is expected a more hydrophilic drug that does not exhibit albumin binding may lead to increased efficacy in addition to improved pharmacokinetics.

English

ISBN: 9781124818016Subjects--Topical Terms:

3173021
Pharmaceutical sciences.
Subjects--Index Terms:

Albumin binding

Paclitaxel-2'-O-pentadecylhemiglutarate: A Prodrug Strategy for Albumin Based Drug Delivery /
LDR:04058nmm a22004573i 4500 001 2435945
005 20251014050546.5
006 m o d
007 cr|nu||||||||
008 261011s2011 miu||||||m |||||||eng d
020 $a 9781124818016
035 $a (MiAaPQD)AAI3464917
035 $a (MiAaPQD)unc:12002
035 $a AAI3464917
040 $a MiAaPQD $b eng $c MiAaPQD $e rda
100 1 $a Hackett, Michael Joseph, $e author. $3 3826434
245 1 0 $a Paclitaxel-2'-O-pentadecylhemiglutarate: A Prodrug Strategy for Albumin Based Drug Delivery / $c Michael Joseph Hackett.
264 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2011
300 $a 1 electronic resource (179 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 73-05, Section: B.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisors: Cho, Moo J.; Juliano, Rudy L. Committee members: Jarstfer, Michael B.; Yuan, Fan; Zhang, Qisheng.
502 $b Ph.D. $c The University of North Carolina at Chapel Hill $d 2011.
520 $a Delivery of antineoplastic agents to solid tumors remains a great challenge in formulation development. Preclinical successes often do not translate into clinical therapies due to the intrinsic imperfections of current models. The presented formulation begins with clinical observations indicating the ubiquitous protein, serum albumin, naturally accumulates selectively in spontaneously developed tumors. Albumin then provides a natural shuttle for therapeutic agents to solid tumors. To test this, a fatty diacid, 3-pentadecylglutaric acid (PDG), was synthesized. This fatty acid has the capacity to bind albumin tightly while concomitantly binding a therapeutic moiety, in this case paclitaxel. The paclitaxel-2'-O-pentadecylhemiglutarate conjugate binds albumin tightly but the extreme hydrophobicity led to poor loading efficiency and the formation of 120 nm albumin aggregates; a similar phenomenon observed in the clinically approved ABRAXANE. This aggregation was found to be the result of a specific interaction between paclitaxel and albumin. Dissociation of the conjugate from albumin is exceedingly slow with less than 3% released over 48 h under sink conditions. When administered to tumor bearing mice, the formulation behaved similarly to covalently attached albumin conjugates. Rapid and uniform organ distribution was observed followed by a slow re-emergence of complex into the vasculature giving rise to a half-life of 23 h. This is comparable to the half-life of the protein itself in mice. Tumor accumulation was moderate (∼1%) and biochemical stability analysis of the conjugate suggests little conversion (<6% over 72 h) to free drug would occur. Despite decreased cytotoxicity, lower doses of the conjugate demonstrated comparable efficacy to TAXOL without the need for surfactants. Modification of paclitaxel was accomplished in a single step using PDG anhydride presenting a cost-effective method for improving the pharmacokinetics of a drug. Conceptually, this study lays the foundation for using the PDG technology for modifying other therapeutic agents. The success of the formulation is highly dependent on the selected therapeutic modality which can be broadly limited to any therapeutic agent bearing a nucleophilic moiety. It is expected a more hydrophilic drug that does not exhibit albumin binding may lead to increased efficacy in addition to improved pharmacokinetics.
546 $a English
590 $a School code: 0153
650 4 $a Pharmaceutical sciences. $3 3173021
653 $a Albumin binding
653 $a Drug delivery
653 $a Natural carriers
653 $a Paclitaxel
653 $a Pentadecylglutaric acid
653 $a Tumor targeting
690 $a 0572
710 2 $a The University of North Carolina at Chapel Hill. $b Pharmaceutical Sciences. $e degree granting institution. $3 3826435
720 1 $a Cho, Moo J. $e degree supervisor.
720 1 $a Juliano, Rudy L. $e degree supervisor.
773 0 $t Dissertations Abstracts International $g 73-05B.
790 $a 0153
791 $a Ph.D.
792 $a 2011
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3464917